Home|Journals|Articles by Year

Directory for Medical Articles
 

Original Article

IJMDC. 2020; 4(9): 1375-1389


Adjuvant TaibUVID nutritional supplements proved promising for novel safe COVID-19 public prophylaxis and treatment: enhancing immunity and decreasing morbidity period for better outcomes (A retrospective study)

Salah Mohamed El Sayed, Saleh A. Bahashwan, Moutasem Salih Aboonq, Hussam Baghdadi, Mo'men Elshzley, Ahmed M. Okashah, Amr Gamal El Rashedy, Rabab AbouElMagd Ahmed, Yasmeen Talal Aljehani, Rehab El-Tahlawi, Manal Mohamed Helmy Nabo, Osama Hamouda, Abdul-Rahman El-Murr, Tamer Mohamed Abdul-Latif, Hany Salah Mahmoud, Mostafa Abu-Elnaga, Mahmoud Mohamed Hassan.


Abstract

Background: We recently suggested TaibUVID nutritional supplements (containing natural honey, Nigella sativa, chamomile, costus, fennel, and/or senna) of prophetic medicine as adjuvants to pharmacological treatments to potentiate immunity and combat the SARS-COV-2 virus and COVID-19 pandemic. The present study aims at assessing the safety and effectiveness of taking adjuvant TaibUVID nutritional supplements.
Methodology: A prospective controlled trial was not applicable. However, a retrospective data analysis of ten confirmed COVID-19 patients (many of them have radiological findings) in Egypt was carried out. Patients knew about the TaibUVID nutritional supplements via social media. An online questionnaire was also distributed via social media to investigate patients’ opinions regarding the safety and effectiveness of taking adjuvant TaibUVID nutritional supplements. Paired sample t-test and Statistical Package for the Social Sciences version 16 were used for data analysis.
Results: TaibUVID induced lymphocytosis and increased the percentage of lymphocytes from 21% to 53.4% within few days, i.e., may increase B lymphocytes (humoral immunity) and T lymphocytes (cell-mediated immunity). COVID-19 patients (n = 3) taking pharmacological treatments only needed a significantly longer duration (p < 0.05) till the beginning of improvement or death (9.66 ± 1.33 days) versus 3.5± 0.22 days for COVID-19 patients who received pharmacological treatments with TaibUVID nutritional supplements (n = 10, majority were physicians). COVID-19 patients (n = 3, all were physicians) taking pharmacological treatments only needed a significantly longer duration (p < 0.05) till complete recovery or death (12.33 ± 2.73 days) versus 7.3 ± 1.01 days for those receiving pharmacological treatments with TaibUVID nutritional supplements (n = 10, majority were physicians). In the questionnaire, 33 out of 40 patients (82.5%) reported no side effects after TaibUVID administration. 7 patients (17.5%) reported few side effects (hyperglycemia and diarrhea) after TaibUVID intake. Diarrhea may be due to senna (recommended but optional). Hyperglycemia may occur with non-natural honey. 38 patients (90%) reported improvement by 25%-100% after intake of TaibUVID nutritional supplements. 20 patients (50%) confirmed getting health benefits after TaibUVID inhalation therapy. 22 patients (55%) reported they know other COVID-19 patients not taking TaibUVID supplements and had delayed improvements.
Conclusion: TaibUVID enhanced immunity and potentiated a safe rapid recovery of COVID-19 infection. It is strongly advisable to add TaibUVID nutritional supplements to pharmacological protocols to fasten patients' recovery. TaibUVID supplements are advisable for public and contacts prophylaxis. "TaibUVID for all" health campaigns are recommended. More clinical research studies are recommended. Limitation: This study is limited by the few number of patients and lack of detailed investigations.

Key words: COVID-19, TaibUVID, TaibUVID Forte, TaibUVID inhalation therapy, Nigella sativa, natural honey, chamomile, senna, fennel, costus






Full-text options


Share this Article



Online Article Submission
• ejmanager.com







eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.